JMKX 1899
Alternative Names: HBI-2438; JMKX-1899Latest Information Update: 18 Dec 2024
Price :
$50 *
At a glance
- Originator Jemincare
- Developer HUYA Bioscience International
- Class Antineoplastics; Small molecules
- Mechanism of Action KRAS protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 10 Jul 2024 Jemincare plans a phase I trial for Solid tumours (In adults, In volunteers) (PO, Tablet) (NCT06473948)
- 01 Apr 2024 Jemincare plans a phase I drug-drug interaction trial for Solid tumours (In volunteers) (PO, Tablet) (NCT06348290)
- 11 Oct 2023 Pharmacodynamics data from a preclinical studies in Cancer presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023 (AACR-NCI-EORTC-2023)